Teva Pharmaceutical Industries (TEVA) Q4 FY2025 earnings: revenue $4.7 billion, up 11.4% on the year
Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $4.7 billion for Q4 FY2025, the quarter ended 31 December 2025, up 11.4% on the same quarter a year earlier. Net income was $481 million, and diluted earnings per share $0.41. The figures are the company's own, from the 10-K it filed with the SEC on 3 February 2026.
Revenue
$4.7 billion
+11.4% on the year · +5.2% on the quarter
Q1 FY2024Q4 FY2025
Operating margin
6.4%
-0.7% a year earlier
Q1 FY2024Q4 FY2025
Net income
$481 million
+11.1% on the quarter
Q1 FY2024Q4 FY2025
Diluted EPS
$0.41
+10.8% on the quarter
Q1 FY2024Q4 FY2025
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 11 new, 2 kept.
2025 revenue rose 4%: Revenue was $17,258 million for 2025, up 4% in U.S. dollars and 3% in local currency. Higher AUSTEDO, AJOVY and UZEDY sales and duvakitug milestone payments were partly offset by the Japan divestment.
Non-GAAP EPS $2.93 for 2025: Non-GAAP diluted EPS was $2.93 for 2025, against $2.49 in 2024. GAAP diluted EPS was $1.21, against a loss of $1.45. Non-GAAP operating margin was 28.4% of revenue.
2025 results above prior expected ranges: The January 11, 2026 presentation gave 2025 ranges, including non-GAAP diluted EPS of $2.55 to $2.65 and free cash flow of $1.6 to $1.9 billion. Reported figures were $2.93 and $2,396 million.
$ million except per share. Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q4 FY2025
Q3 FY2025
Q4 FY2024
On the quarter
On the year
Last 8 quarters
Operating cash flow
1,158
369
575
+213.8%
+101.4%
Capital expenditure
142
136
129
+4.4%
+10.1%
Free cash flow
1,016
233
446
+336.1%
+127.8%
Free cash flow margin
21.6%
5.2%
10.5%
Cash from investing
165
135
202
+22.2%
-18.3%
Cash from financing
40.0
-453
-674
Depreciation and amortisation
258
249
269
+3.6%
-4.1%
Share-based compensation
51.0
34.0
34.0
+50.0%
+50.0%
Diluted shares, weighted
1,173m
1,164m
1,157m
+0.8%
+1.4%
Shares outstanding at period end
1,150m
1,147m
1,134m
+0.2%
+1.4%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q4 FY2025
Q3 FY2025
Q4 FY2024
On the quarter
On the year
Last 8 quarters
Shareholders' equity
7,910
7,250
5,373
+9.1%
+47.2%
Non-controlling interest
4.0
4.0
7.0
0.0%
-42.9%
Redeemable equity
0.0
0.0
340
Debt
16,806
16,790
17,783
+0.1%
-5.5%
Operating lease liabilities
288
283
296
+1.8%
-2.7%
Other liabilities
15,740
15,529
15,527
+1.4%
+1.4%
Total liabilities and equity
40,748
39,856
39,326
+2.2%
+3.6%
Fixed assets
4,080
4,820
4,581
-15.4%
-10.9%
Goodwill
16,000
15,945
15,147
+0.3%
+5.6%
Intangible assets
3,781
3,936
4,418
-3.9%
-14.4%
Cash and equivalents
3,556
2,203
3,300
+61.4%
+7.8%
Receivables
3,709
3,810
3,059
-2.7%
+21.2%
Inventory
3,179
3,323
3,007
-4.3%
+5.7%
Other assets
6,443
5,819
5,814
+10.7%
+10.8%
Total assets
40,748
39,856
39,326
+2.2%
+3.6%
Questions
What was Teva Pharmaceutical Industries' revenue in Q4 FY2025?
Teva Pharmaceutical Industries (TEVA) reported revenue of $4.7 billion for Q4 FY2025, the quarter ended 31 December 2025, up 11.4% on the same quarter a year earlier.
How much did Teva Pharmaceutical Industries earn in Q4 FY2025?
Net income for Q4 FY2025 was $481 million, and diluted earnings per share $0.41.
When did Teva Pharmaceutical Industries report Q4 FY2025 results?
Teva Pharmaceutical Industries filed its 10-K for the year that ended with the quarter on 3 February 2026; the fourth quarter is the year less the first three.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-K for the period ended 31 December 2025, filed 3 February 2026: the filing.